HK1254976A1 - 造血幹細胞和抗癌免疫檢查點抑制劑的組合療法 - Google Patents

造血幹細胞和抗癌免疫檢查點抑制劑的組合療法

Info

Publication number
HK1254976A1
HK1254976A1 HK18114083.9A HK18114083A HK1254976A1 HK 1254976 A1 HK1254976 A1 HK 1254976A1 HK 18114083 A HK18114083 A HK 18114083A HK 1254976 A1 HK1254976 A1 HK 1254976A1
Authority
HK
Hong Kong
Prior art keywords
stem cells
hematopoietic stem
immune checkpoint
against cancer
checkpoint inhibitors
Prior art date
Application number
HK18114083.9A
Other languages
English (en)
Inventor
Duane Mitchell
Catherine Flores
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of HK1254976A1 publication Critical patent/HK1254976A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18114083.9A 2015-07-31 2018-11-05 造血幹細胞和抗癌免疫檢查點抑制劑的組合療法 HK1254976A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562199916P 2015-07-31 2015-07-31
US201662296866P 2016-02-18 2016-02-18
US201662296849P 2016-02-18 2016-02-18
US201662296826P 2016-02-18 2016-02-18
PCT/US2016/044718 WO2017023753A1 (en) 2015-07-31 2016-07-29 Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer

Publications (1)

Publication Number Publication Date
HK1254976A1 true HK1254976A1 (zh) 2019-08-02

Family

ID=57943813

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114083.9A HK1254976A1 (zh) 2015-07-31 2018-11-05 造血幹細胞和抗癌免疫檢查點抑制劑的組合療法

Country Status (8)

Country Link
US (2) US10660954B2 (zh)
EP (1) EP3328896A4 (zh)
JP (2) JP7062290B2 (zh)
KR (1) KR20180029079A (zh)
AU (2) AU2016303489B2 (zh)
CA (1) CA2994241A1 (zh)
HK (1) HK1254976A1 (zh)
WO (1) WO2017023753A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660954B2 (en) 2015-07-31 2020-05-26 University Of Florida Research Foundation, Incorporated Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
JP7114095B2 (ja) 2016-12-21 2022-08-08 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する
MX2019008205A (es) 2017-01-20 2020-01-23 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de células cd137+.
US10300090B2 (en) 2017-03-15 2019-05-28 Orca Biosystems, Inc. Compositions of hematopoietic stem cell transplants
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11033622B2 (en) 2017-05-25 2021-06-15 Leidos, Inc. PD-1 and CTLA-4 dual inhibitor peptides
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
JP7330196B2 (ja) * 2018-01-18 2023-08-21 ユートロピクス ファーマシューティカルズ， インコーポレイテッド がん薬物応答性を予測する方法
JP2021513524A (ja) * 2018-02-05 2021-05-27 テサロ， インコーポレイテッド 小児用ニラパリブ製剤および小児向け処置方法
WO2019157158A2 (en) 2018-02-08 2019-08-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for allogenic hematopoietic stem cell transplantation
TWI723354B (zh) 2018-03-21 2021-04-01 中國醫藥大學 用於癌症治療之工程化幹細胞
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP4054591A1 (en) * 2019-11-04 2022-09-14 Astrazeneca AB Combination therapy for treating cancer
JP2023521671A (ja) * 2020-04-03 2023-05-25 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法
WO2021247789A1 (en) 2020-06-04 2021-12-09 Leidos, Inc. Immunomodulatory compounds
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRAL BODY WITH CRYOPROTECTIVE USING VACUUM-ASSISTED DIFFUSION
EP4225444A1 (en) 2020-10-12 2023-08-16 Leidos, Inc. Immunomodulatory peptides
EP4228406A1 (en) 2020-10-14 2023-08-23 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
CN114788877B (zh) * 2022-03-24 2023-11-24 苏州大学 一种基因工程化造血干细胞给药系统及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
SI2206517T1 (sl) 2002-07-03 2023-12-29 Ono Pharmaceutical Co., Ltd. Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1
DK1558648T3 (da) 2002-10-17 2012-04-23 Genmab As Humane monoklonale antistoffer mod cd20
WO2006116181A2 (en) 2005-04-25 2006-11-02 Trustees Of Dartmouth College Regulatory t cell mediator proteins and uses thereof
US7960434B2 (en) 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
WO2009114725A2 (en) * 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
KR20110050529A (ko) 2008-08-25 2011-05-13 앰플리뮨, 인크. Ｐｄ-１ 길항제의 조성물 및 사용 방법
KR101924874B1 (ko) 2008-09-26 2018-12-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
US10570204B2 (en) * 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
US10660954B2 (en) 2015-07-31 2020-05-26 University Of Florida Research Foundation, Incorporated Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer

Also Published As

Publication number Publication date
JP2018522901A (ja) 2018-08-16
CA2994241A1 (en) 2017-02-09
JP7062290B2 (ja) 2022-05-06
JP2022033776A (ja) 2022-03-02
KR20180029079A (ko) 2018-03-19
EP3328896A4 (en) 2019-08-07
US20210008200A1 (en) 2021-01-14
US10660954B2 (en) 2020-05-26
US20180214544A1 (en) 2018-08-02
US11904016B2 (en) 2024-02-20
EP3328896A1 (en) 2018-06-06
AU2016303489B2 (en) 2023-02-16
AU2016303489A1 (en) 2018-02-15
AU2023203038A1 (en) 2023-06-08
WO2017023753A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
HK1254976A1 (zh) 造血幹細胞和抗癌免疫檢查點抑制劑的組合療法
IL286282A (en) Use of palinabolin in combination with immune checkpoint inhibitors
HK1243005A1 (zh) 抗lilrb抗體及其在檢測和治療癌症中的用途
IL251774A0 (en) Methods and preparations for dosing in stress cell therapy
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
SG10201912978PA (en) Methods for improving the efficacy and expansion of immune cells
HUE043847T2 (hu) Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL256467B (en) A control block and a whole-cell microbacterium for the treatment of cancer
GB201510758D0 (en) Novel TNFa structure for use in therapy
PL3303778T3 (pl) Ulepszenia w magazynowaniu energi
HK1249852A1 (zh) 與癌症藥物的聯合治療中的nk-92細胞
HK1246165A1 (zh) 細胞內atp增強劑
GB201510292D0 (en) Improvements in Dosimetry Techniques for Radiotherapy
IL246607B (en) Improved cellular preparations and methods for cancer treatment
SG11201704916TA (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
GB201510288D0 (en) Improvements in dosimetry techniques for radiotherapy
GB201613078D0 (en) Stem cells and cancer
IL252118A0 (en) Analytical methods and arrays for their use
HK1252514A1 (zh) 包含與抗體組合施予的ido抑制劑的腫瘤治療劑
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
IL266116A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use
GB201410226D0 (en) Methods and arrays for use in the same
GB201511419D0 (en) The use of bioinformatic data in autolobous cell therapies
GB201511158D0 (en) Cell modification and application in therapy